arrow
E

Elizabeth B. Hirsch

University of Minnesota
H指数:25
被引数:2,745

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Introduction and Methods
2025-12-300
PRE
Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Duration of Antibiotics for Complicated UTI
2025-12-200
PRE
Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Timing of Intravenous to Oral Antibiotics Transition for Complicated UTI
2025-12-190
PRE
Evaluation of cefazolin <3 g vs. 3 g treatment doses for cellulitis in patients who weigh≥120 kg within a large, community health system via modified desirability of outcomes ranking (DOOR) methodology

Gens, K.D.; Gagnon, B.R.; Claeys, K.C.; Wankum, M.A.; Hirsch, E.B. 通过改良的结局可取性排序(DOOR)方法学,在大型社区健康系统中评估头孢唑林<3 g与3 g治疗剂量对体重≥120 kg患者的蜂窝织炎的疗效。J. Infect. Chemother. 2025, 31, 102833. [Google Scholar] [CrossRef]

2025-11-011
PRE
Into the Unknown: Practical Remdesivir Restriction in the Era of Widespread Severe Acute Respiratory Syndrome Coronavirus 2 Seropositivity

进入未知:在广泛存在严重急性呼吸综合征冠状病毒2血清阳性的时代,瑞德西韦的实用限制

2025-04-250
PRE
Heteroresistance associated with the production of fosfomycin-resistant inner colonies during disk diffusion testing among a geographically diverse collection of Klebsiella pneumoniae clinical isolates

在地理上不同的肺炎克雷伯菌临床分离株中进行圆盘扩散测试期间,与磷霉素抗性内部菌落产生相关的异质性

2025-02-200
OAAI